Treatment of Complications of Peripheral Obstructive Arterial Disease with Prostaglandin E

Killion, Dennis D.; Ambrus, Julian L.
July 1987
Angiology;Jul1987, Vol. 38 Issue 7, p507
Academic Journal
Forty-one subjects diagnosed with complications of peripheral obstructive arterial disease were treated with continuous infusions of Prostaglandin E, (PGE1) over a three-week period during 1981–1982 in an open-label, uncontrolled study under ward conditions. Ischemic rest pain and ulcers were treated with intravenous infusions of PGE1 at dose rates of 14–21 ng kg-1 min-1 for seventy hours, once a week. Symptomatic relief of rest pain and spontaneous healing of stable ulcers occurred. Whereas classically dependable noninvasive circulation evaluations were not prognostic of the treatment's success, they did suggest local and rheological changes rather than a generalized vasodilation. The PGE1 infusion is efficacious for an unknown length of time, which may somehow be related to inhibition of platelet aggregation. Since transient ischemic attack (TIA) and cerebrovascular accident (CVA) were found to be associated with PGE, infusion, cerebrovascular evaluation must be conducted prior to considering PGE, replacement therapy for the individual patient.


Related Articles

  • Pharmacologic Preconditioning Effects: Prostaglandin E1 Induces Heat-Shock Proteins Immediately After Ischemia/Reperfusion of the Mouse Liver Matsuo, Ken-ichi; Togo, Shinji; Sekido, Hitoshi; Morita, Tomoyuki; Kamiyama, Masako; Morioka, Daisuke; Kubota, Toru; Miura, Yasuhiko; Tanaka, Kuniya; Ishikawa, Takashi; Ichikawa, Yasushi; Endo, Itaru; Goto, Hitoshi; Nitanda, Hiroyuki; Okazaki, Yasushi; Hayashizaki, Yoshihide; Shimada, Hiroshi // Journal of Gastrointestinal Surgery;Jul2005, Vol. 9 Issue 6, p758 

    Prostaglandin E1 (PGE1) has several potential therapeutic effects, including cytoprotection, vasodilation, and inhibition of platelet aggregation. This study investigates the protective action of PGE1 against hepatic ischemia/reperfusion injury in vivo using a complementary DNA microarray. PGE1...

  • Prostaglandin E2 acts via the EP4 receptor to inhibit platelet aggregation. Philipose, Sonia; Ofner, Martina; Heinemann, Ákos; Schuligoi, Rufina // BMC Pharmacology;2009 Supplement 2, Vol. 9, Special section p1 

    Background Platelets play a central role in haemostasis. Blood vessel injury leads to platelet aggregation and also invokes an inflammatory response leading to the formation of prostanoids like prostaglandin E2 (PGE2) and prostacyclin (PGI2). It is known that low concentrations of PGE2 enhance...

  • Limaprost: A Viewpoint by Akira Dezawa. Dezawa, Akira // Drugs;2007, Vol. 67 Issue 1, p119 

    Fenofibrate is a fibric acid derivative indicated for use in the treatment of primary hypercholesterolaemia, mixed dyslipidaemia and hypertriglyceridaemia in adults who have not responded to nonpharmacological measures. Its lipid-modifying effects are mediated by activation of peroxisome...

  • Limaprost. Harrison, Tracy Swainston; Plosker, Greg L. // Drugs;2007, Vol. 67 Issue 1, p109 

    â–´ Limaprost, an alprostadil (prostaglandin E1) analogue, is a vasodilator that increases blood flow and inhibits platelet aggregation.â–´ The efficacy of oral limaprost was evaluated in adult Japanese patients in three randomised, double-blind, 6-week trials. One study included...

  • Novolizer®: A Multidose Dry Powder Inhaler. Fenton, Caroline; Keating, Gillian M.; Plosker, Greg L. // Drugs;2003, Vol. 63 Issue 22, p2437 

    ▴ Novolizer[sup ®] is a multidose breath-actuated dry powder inhaler (DPI) approved for use with salbutamol (albuterol) and budesonide. It has multiple patient feedback mechanisms and an inspiratory flow rate threshold designed to optimise dosage. ▴ In two studies, children aged...

  • The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. Abe, Yasunobu; Inamori, Masahiko; Togawa, Jun-Ichi; Kikuchi, Taisuke; Muramatsu, Kenichi; Chiguchi, Gaku; Kawamura, Harunobu; Kobayashi, Noritoshi; Kirikoshi, Hiroyuki; Sakaguchi, Takashi; Takamura, Tomoo; Nakajima, Atsushi; Ueno, Norio; Sekihara, Hisahiko // Journal of Gastroenterology;2004, Vol. 39 Issue 1, p21 

    Background Methods. Ten healthy Helicobacter pylori-negative male subjects participated in this randomized, double-masked, two-way crossover study. Intragastric pH was monitored continuously for 4 h after a single intravenous administration of omeprazole 20 mg and after a single intravenous...

  • Rationale for the use of platelet aggregation inhibitors in PAD patients. Agnelli, G. // Vascular Medicine;2001 Supplement 1, Vol. 6, p13 

    Peripheral arterial disease (PAD) is a major risk marker for systemic ischaemic events. The understanding of PAD has moved from PAD as an organ-specific disease to PAD as the lower-limb localization of a multifocal disease, i.e. atherothrombosis. Blood platelet activation and aggregation is a...

  • Interaction Potential and Tolerability of the Coadministration of Cilostazol and Aspirin. Mallikaarjun, S.; Forbes, W.P.; Bramer, S.L. // Clinical Pharmacokinetics;1999 Supplement, Vol. 37 Issue 6, p87 

    Objective: This study evaluated the effects of repeated oral drug administration with cilostazol alone and with aspirin (acetylsalicylic acid) on platelet aggregation, coagulation and bleeding time as well as the cilostazol-aspirin pharmacokinetic interaction in healthy males. Design: This was a...

  • A randomized trial of iloprost in patients with intermittent claudication. Creager, Mark A.; Pande, Reena L.; Hiatt, William R. // Vascular Medicine;2008, Vol. 13 Issue 1, p5 

    Prostanoids, which promote vasodilation and reduce platelet aggregation, have been proposed as candidate therapies for intermittent claudication due to peripheral arterial disease (PAD). However, studies of these medications have yielded inconsistent results. This study tested the hypothesis...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics